CCN2 and cancer: For instance, FG-3019 (Pamrevlumab), a monoclonal antibody targeting connective tissue growth factor (CTGF), has been shown to disrupt the interaction between cancer cells and cancer-associated fibroblasts (CAFs), which are key players in remodeling the extracellular matrix and promoting tumor growth [31, 32].